财经快讯|迈普医学:可吸收多层纤丝型再生氧化纤维素尚处于临床试验阶段
迈普医学近期接受投资者调研时称,公司的可吸收再生氧化纤维素是专门针对神经外科手术止血需求所开发的高性能止血产品,公司实现了该产品的国产化。自首次取得国内医疗器械注册证以来,积极推进国内各省市地区的挂网。2022年度公司产品在海内外临床使用超过5万片。此外,公司积极推进该产品的扩适应症工作,延伸至其他外科领域,“可吸收多层纤丝型再生氧化纤维素”尚处于临床试验阶段,其顺利产业化将有望快速提升公司止血材料市场渗透率,与进口品牌在全外科领域上展开竞争。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Oil steady as demand worries face tight supply outlook By Reuters
Gold: After Mini-Crash to Below $2,000, What’s the Chance for Upside?
Related News
![](/images/page_blank@2x.png)